Structural basis of respiratory syncytial virus neutralization by motavizumab (original) (raw)

Nature Structural & Molecular Biology volume 17, pages 248–250 (2010)Cite this article

Subjects

Abstract

Motavizumab is ∼tenfold more potent than its predecessor, palivizumab (Synagis), the FDA-approved monoclonal antibody used to prevent respiratory syncytial virus (RSV) infection. The structure of motavizumab in complex with a 24-residue peptide corresponding to its epitope on the RSV fusion (F) glycoprotein reveals the structural basis for this greater potency. Modeling suggests that motavizumab recognizes a different quaternary configuration of the F glycoprotein than that observed in a homologous structure.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 12 print issues and online access

$209.00 per year

only $17.42 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Similar content being viewed by others

Accession codes

Primary accessions

Protein Data Bank

References

  1. World Health Organization. Acute respiratory infection (World Health Organization, Geneva, 2009; accessed 6 January 2010). <http://www.who.int/vaccine_research/diseases/ari/en/index.html>
  2. Thompson, W.W. et al. J. Am. Med. Assoc. 289, 179–186 (2003).
    Article Google Scholar
  3. Groothuis, J.R., Simoes, E.A. & Hemming, V.G. Pediatrics 95, 463–467 (1995).
    CAS PubMed Google Scholar
  4. Johnson, S. et al. J. Infect. Dis. 176, 1215–1224 (1997).
    Article CAS Google Scholar
  5. Beeler, J.A. & van Wyke Coelingh, K. J. Virol. 63, 2941–2950 (1989).
    CAS PubMed PubMed Central Google Scholar
  6. Arbiza, J. et al. J. Gen. Virol. 73, 2225–2234 (1992).
    Article CAS Google Scholar
  7. Lopez, J.A. et al. J. Gen. Virol. 74, 2567–2577 (1993).
    Article Google Scholar
  8. The IMpact-RSV Study Group. Pediatrics 102, 531–537 (1998).
  9. Wu, H. et al. J. Mol. Biol. 368, 652–665 (2007).
    Article CAS Google Scholar
  10. Wu, H. et al. J. Mol. Biol. 350, 126–144 (2005).
    Article CAS Google Scholar
  11. Johnson, L.S. & Braden, B. USPTO Patent 7229618 (2007).
  12. Smith, B.J., Lawrence, M.C. & Colman, P.M. Protein Eng. 15, 365–371 (2002).
    Article CAS Google Scholar
  13. Krissinel, E. & Henrick, K. J. Mol. Biol. 372, 774–797 (2007).
    Article CAS Google Scholar
  14. Lawrence, M.C. & Colman, P.M. J. Mol. Biol. 234, 946–950 (1993).
    Article CAS Google Scholar
  15. Zhao, X., Chen, F.-P., Megaw, A.G. & Sullender, W.M. J. Infect. Dis. 190, 1941–1946 (2004).
    Article CAS Google Scholar
  16. Tous, G.I., Schenerman, M.A., Casas-Finet, J., Wei, Z. & Pfarr, D.S. USPTO Patent application 11/230,593 (2006).
  17. Yin, H.S., Wen, X., Paterson, R.G., Lamb, R.A. & Jardetzky, T.S. Nature 439, 38–44 (2006).
    Article CAS Google Scholar
  18. Tao, Y., Strelkov, S.V., Mesyanzhinov, V.V. & Rossmann, M.G. Structure 5, 789–798 (1997).
    Article CAS Google Scholar
  19. Lok, S.-M. et al. Nat. Struct. Mol. Biol. 15, 312–317 (2008).
    Article CAS Google Scholar
  20. Liu, J., Bartesaghi, A., Borgnia, M.J., Sapiro, G. & Subramaniam, S. Nature 455, 109–113 (2008).
    Article CAS Google Scholar

Download references

Acknowledgements

The authors would like to thank L. Shapiro and members of the Structural Biology Section, Vaccine Research Center, for helpful comments, and J. Gonczy and the staff at SER-CAT (Southeast Regional Collaborative Access Team) for help with X-ray diffraction data collection. Support for this work was provided by the Intramural Research Program (US National Institute of Allergy and Infectious Diseases). Use of insertion device 22 (SER-CAT) at the Advanced Photon Source was supported by the US Department of Energy, Basic Energy Sciences, Office of Science, under contract W-31-109-Eng-38.

Author information

Authors and Affiliations

  1. Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Jason S McLellan, Man Chen, Albert Kim, Yongping Yang, Barney S Graham & Peter D Kwong

Authors

  1. Jason S McLellan
    You can also search for this author inPubMed Google Scholar
  2. Man Chen
    You can also search for this author inPubMed Google Scholar
  3. Albert Kim
    You can also search for this author inPubMed Google Scholar
  4. Yongping Yang
    You can also search for this author inPubMed Google Scholar
  5. Barney S Graham
    You can also search for this author inPubMed Google Scholar
  6. Peter D Kwong
    You can also search for this author inPubMed Google Scholar

Contributions

J.S.M., B.S.G. and P.D.K. designed experiments and analyzed data; J.S.M. also prepared, crystallized and solved the structure of the motavizumab–peptide complex and performed the biochemical and biophysical experiments; M.C. performed the neutralization experiments; Y.Y. and A.K. expressed and purified the RSV F0 Fd glycoprotein and motavizumab IgG, respectively.

Corresponding author

Correspondence toPeter D Kwong.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Rights and permissions

About this article

Cite this article

McLellan, J., Chen, M., Kim, A. et al. Structural basis of respiratory syncytial virus neutralization by motavizumab.Nat Struct Mol Biol 17, 248–250 (2010). https://doi.org/10.1038/nsmb.1723

Download citation

This article is cited by